REPOTRECTINIB | REPOTRECTINIB | ANTINEOPLASTIC TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER INHIBITOR OF PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS1 (ROS1) AND OF THE TROPOMYOSIN RECEPTOR TYROSINE KINASES (TRKS) TRKA, TRKB, AND TRKC | ORAL | Cmax 2 MICROMOLAR Tmax 2.5 HOUR F 45.7 PERCENT VD 432 LITER PPB 95.4 PERCENT Cl 15.9 LITER / HOUR HT 50.6 HOUR | TYROSINE-PROTEIN KINASE ROS1 PDB 7VKN (CRYSTAL STRUCTURE OF TRKA (G595R) KINASE WITH REPOTRECTINIB) LIGAND CODE = 7GI (link to the list of PDB complexes) Download experimental 3D coordinates of 7GI with added hydrogens | - more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |